JP2005533104A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533104A5
JP2005533104A5 JP2004521488A JP2004521488A JP2005533104A5 JP 2005533104 A5 JP2005533104 A5 JP 2005533104A5 JP 2004521488 A JP2004521488 A JP 2004521488A JP 2004521488 A JP2004521488 A JP 2004521488A JP 2005533104 A5 JP2005533104 A5 JP 2005533104A5
Authority
JP
Japan
Prior art keywords
composition
compound
composition according
och
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004521488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533104A (ja
Filing date
Publication date
Priority claimed from US10/195,824 external-priority patent/US6727272B1/en
Application filed filed Critical
Publication of JP2005533104A publication Critical patent/JP2005533104A/ja
Publication of JP2005533104A5 publication Critical patent/JP2005533104A5/ja
Ceased legal-status Critical Current

Links

JP2004521488A 2002-07-15 2003-06-25 慢性関節リウマチを処置するためのレフルノミド類似体 Ceased JP2005533104A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/195,824 US6727272B1 (en) 2002-07-15 2002-07-15 Leflunomide analogs for treating rheumatoid arthritis
PCT/US2003/019956 WO2004006834A2 (en) 2002-07-15 2003-06-25 Leflunomide analogs for treating rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010108822A Division JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Publications (2)

Publication Number Publication Date
JP2005533104A JP2005533104A (ja) 2005-11-04
JP2005533104A5 true JP2005533104A5 (enExample) 2006-06-29

Family

ID=30115011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004521488A Ceased JP2005533104A (ja) 2002-07-15 2003-06-25 慢性関節リウマチを処置するためのレフルノミド類似体
JP2010108822A Pending JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010108822A Pending JP2010168402A (ja) 2002-07-15 2010-05-10 慢性関節リウマチを処置するためのレフルノミド類似体

Country Status (5)

Country Link
US (1) US6727272B1 (enExample)
EP (1) EP1539143A4 (enExample)
JP (2) JP2005533104A (enExample)
AU (1) AU2003251611A1 (enExample)
WO (1) WO2004006834A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US7125902B2 (en) * 2004-05-28 2006-10-24 Unitech Pharmaceuticals, Inc. Methods, compounds, and diagnostics for cancer treatment
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 免疫増強用の化合物
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
KR20080038339A (ko) * 2005-08-31 2008-05-06 코와 가부시키가이샤 관절 류머티즘의 예방 및/또는 치료법
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CN101563082A (zh) * 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
KR20090069309A (ko) * 2006-09-22 2009-06-30 랜박시 래보러터리스 리미티드 포스포디에스터라제 타입-ⅳ의 저해제
US20080085912A1 (en) * 2006-10-06 2008-04-10 Unitech Pharmaceuticals, Inc. Isoxazole derivatives and methods of treating diseases
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH レフルノミドおよびマロノニトリラマイドの新規の使用
EP2670753B1 (en) 2011-01-31 2016-10-19 Novartis AG Novel heterocyclic derivatives
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
SG10201608469RA (en) 2012-05-16 2016-11-29 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
RU2722316C2 (ru) * 2015-06-17 2020-05-29 Биокон Лимитед Новый способ получения терифлуномида
MX2018005298A (es) 2015-11-02 2018-06-22 Novartis Ag Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN108863970A (zh) * 2017-08-14 2018-11-23 四川省中医药转化医学中心 新化合物及其在治疗炎症或炎症相关疾病方面的应用
KR102696521B1 (ko) * 2021-11-24 2024-08-20 한양대학교 에리카산학협력단 이속사졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1533347A (en) * 1976-10-22 1978-11-22 Pfizer Ltd Anthelmintic compounds
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
DE59009528D1 (de) * 1989-09-22 1995-09-21 Basf Ag Carbonsäureamide.
US5814646A (en) * 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
DE19702988A1 (de) 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination

Similar Documents

Publication Publication Date Title
JP2005533104A5 (enExample)
JP2011513196A5 (enExample)
JP2007533752A5 (enExample)
JP2016503786A5 (enExample)
JP2006526031A5 (enExample)
JP2007508360A5 (enExample)
JP2017222722A5 (enExample)
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
JP2010526025A5 (enExample)
JP2005511547A5 (enExample)
JP2006518728A5 (enExample)
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
JP2010511631A5 (enExample)
JP2006515626A5 (enExample)
JP2007514005A5 (enExample)
JP2005516967A5 (enExample)
JP2007533722A5 (enExample)
JP2004532828A5 (enExample)
JP2006502187A5 (enExample)
JP2006504738A5 (enExample)
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
JP2019537608A5 (enExample)
JP2019501948A5 (enExample)
JP2005522492A5 (enExample)
JP2009503045A5 (enExample)